Subscribe: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies
http://img.marketwire.com/rss/mwPBES.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  clinical  company  conference  development  feb  february  marketwired feb  marketwired  new  offering  products  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies

Marketwired - Equipment and Supplies



Marketwired - Equipment and Supplies



Last Build Date: Mon, 20 Feb 2017 05:34:34 EST

Copyright: Copyright: (C) Marketwired
 



Phoseon Technology Exhibits LED Solutions for Life Sciences at Pittcon 2017

Mon, 20 Feb 2017 05:00:00 EST

Visit the Phoseon booth to learn more about LED solutions for life sciences applications




Model N to Present CPQ and Tendering Strategies at the 4th Annual Medical Device Commercial Leaders Forum

Mon, 20 Feb 2017 02:00:00 EST

Join Model N to learn industry trends and best practices for optimal global pricing and tendering in the Medical Device industry




Taconic Biosciences gera modelo de camundongo de síndrome de Vici

Fri, 17 Feb 2017 17:36:45 EST

CRISPR acelera a disponibilidade da ferramenta vital para pesquisas




Taconic Biosciences genera modelo de ratón del síndrome de Vici

Fri, 17 Feb 2017 17:22:57 EST

CRISPR acelera disponibilidad de herramienta de investigación vital




Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Fri, 17 Feb 2017 16:01:00 EST

LEXINGTON, MA--(Marketwired - Feb 17, 2017) -  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the closing of its previously announced underwritten public offering. Aldeyra sold 2,555,555 shares of its common stock, including 333,333 shares sold in connection with the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds of the offering, including the full exercise of the option, were approximately $10.5 million, after deducting the underwriting discounts and commissions and the other estimated offering expenses payable by Aldeyra.




Taconic Biosciences Generates Vici Syndrome Mouse Model

Fri, 17 Feb 2017 12:03:21 EST

CRISPR Accelerates Availability of Vital Research Tool




Nephros to Present at the SeeThruEquity 3nd Annual Innovations Investor Conference on Feb. 22, 2016

Thu, 16 Feb 2017 18:27:43 EST

RIVER EDGE, NJ--(Marketwired - Feb 16, 2017) - Nephros, Inc. (OTCQB: NEPH) (the "Company"), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), will present at the SeeThruEquity 3nd Annual Innovations Investor Conference at The W Hotel in Miami on South Beach on February 22, 2017.




Progressive Care Slated to Present at SeeThru Equity Conference in Miami

Thu, 16 Feb 2017 16:19:56 EST

MIAMI, FL--(Marketwired - February 16, 2017) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, announces that it will be presenting at the SeeThru Equity & Brewer Group 3nd Annual Innovations and Investor Conference on February 22, 2017.




Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)

Thu, 16 Feb 2017 11:05:00 EST

Comments Delivered During Presentation at RHK Capital 2017 Disruptive Growth & Healthcare Conference at 10:45 a.m. ET Today




PAC Machinery Introduces MedLogic Control System for Validatable Medical Impulse Sealers

Thu, 16 Feb 2017 09:30:00 EST

The MedLogic control system provides consistent process accuracy with storage and output of all parameters required for validation and back up; In addition, date, time, operator login, bag count, and any alarm condition is captured and stored




Hospital Sisters Health System Contracts with LogicStream Health for Clinical Process Measurement

Thu, 16 Feb 2017 09:30:00 EST

MINNEAPOLIS, MN--(Marketwired - Feb 16, 2017) - LogicStream Health, Inc. announced today that Hospital Sisters Health System (HSHS) has signed an agreement to implement its Clinical Process Measurement solutions. Delivering highly reliable healthcare is HSHS's number one goal in signing the three-year agreement with LogicStream.




The Alliance for Regenerative Medicine Publishes Position on Hospital Exemption of Advanced Therapy Medicinal Products in Europe

Thu, 16 Feb 2017 09:17:02 EST

BRUSSELS, BELGIUM and WASHINGTON, DC--(Marketwired - Feb 16, 2017) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine and advanced therapies sector, today announced it has published its position on Hospital Exemption (HE) in response to vastly different interpretations and implementations across the European Union of Article 3(7) of Directive 2001/83/EC within article 28 (2) of the Advanced Therapy Medicinal Products (ATMP) Regulation.




Model N Announces Howard Dean and Tom Coburn as Keynote Speakers at Rainmaker 2017

Thu, 16 Feb 2017 09:00:00 EST

Join industry leaders for a thought provoking debate on the future of Healthcare and global businesses at Model N's 13th annual Revenue Management Conference




Vitality Biopharma to Present at SeeThruEquity 3rd Annual Innovations Investor Conference in Miami

Thu, 16 Feb 2017 08:55:00 EST

LOS ANGELES, CA--(Marketwired - Feb 16, 2017) - Vitality Biopharma, Inc. (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise there will be a corporate presentation at the SeeThruEquity 3rd Annual Innovations Investor Conference to be held on Wednesday, February 22nd at the W Hotel, in South Beach, Miami.




Amfil Technologies Inc. Expands on its GROzone Product Line Which Is Designed to Eliminate Pesticide Use in the Medical Marijuana Industry

Thu, 16 Feb 2017 08:00:00 EST

TORONTO, ON--(Marketwired - Feb 16, 2017) - Amfil Technologies Inc. (OTC PINK: AMFE) is pleased to give an overview of its GROzone product line and where it stands today.




Endexx Reports First Quarter Revenue Growth of 31%

Thu, 16 Feb 2017 08:00:00 EST

Company generates 29% sequential quarterly growth driven by new product introductions and recurring revenue stream




Medigus Receives Approval for Commencement of the First Multi-Center MUSE Clinical Study from CFDA in China

Thu, 16 Feb 2017 07:00:00 EST

OMER, ISRAEL--(Marketwired - Feb 16, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that the China Food and Drug Administration, or CFDA, has approved the commencement of the first multi-center MUSET Clinical Study in China.




Akers Biosciences Allowed US Patent for Akers Wellness(TM) Tests Cartridge

Thu, 16 Feb 2017 07:00:00 EST

THOROFARE, NJ--(Marketwired - Feb 16, 2017) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces that the United States Patent and Trademark Office has allowed a patent covering Akers Bio's proprietary cartridge for the optical scanning device utilized in the Company's BreathScan LyncT technology. BreathScan LyncT is the new bluetooth-enabled reading device from Akers WellnessT which enables users to track the results of Akers WellnessT breath-based tests via their mobile device.




Revive Therapeutics Announces Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases

Thu, 16 Feb 2017 07:00:00 EST

TORONTO, ONTARIO--(Marketwired - Feb. 16, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced the Company is expanding its product pipeline through the development of cannabinoid-based therapeutics targeting liver diseases.




Vinergy Resources/MJ BioPharma Appoint John Simon to Scientific Advisory Board

Thu, 16 Feb 2017 07:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 16, 2017) - Vinergy Resources Ltd. ("Vinergy" or the "Company") (CSE:VIN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ BioPharma (announced December 14, 2016) is pleased to announce that, as a part of the Company's strategy to develop a lab for research and development products that test and identify specific cannabinoid isolates for targeted therapeutic purposes, it has appointed John Simon to the Company's Scientific Advisory Board (SAB).




CipherCloud Wins Nine 2017 Info Security Products Guide (ISPG) Global Excellence Awards at RSA 2017

Thu, 16 Feb 2017 06:00:00 EST

CipherCloud's multi-cloud security platform, mobile app and customer service gain industry recognition




Ogilvy Healthworld takes home Silver at the 2016 PM Society Awards

Wed, 15 Feb 2017 12:06:04 EST

PARSIPPANY, NJ--(Marketwired - Feb 15, 2017) - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP company (NASDAQ: WPPGY) (www.wpp.com), today announced its London-based Ogilvy Healthworld agency was awarded a Silver recognition at the PM Society Awards on Friday, February 3rd at the Grosvenor House Hotel in London, UK.




PotNetwork's Diamond CBD Scores Over $250,000 in Purchase Orders at the 36th Las Vegas CHAMPS Event

Wed, 15 Feb 2017 10:06:17 EST

Results Exceeded Expectation as Diamond CBD's Robust Product Line was Showcased at the World's Largest and Most Trusted Counter-Culture Trade Show




Asterand Bioscience and MolecularMD announce a partnership to accelerate targeted therapeutic biomarker validation, optimization, development and commercialization

Wed, 15 Feb 2017 10:00:00 EST

Partnership facilitates therapeutic biomarker and target validation, assay development and clinical trial management for companion diagnostics and drug development




MEDIA ALERT: Impinj Hosts Executives from Four of the Country's Leading Healthcare Facilities to Discuss How They're Using IoT to Improve Efficiency and Deliver High Quality Patient Care

Wed, 15 Feb 2017 10:00:00 EST

SEATTLE, WA--(Marketwired - Feb 15, 2017) - HIMSS -- As the healthcare industry grapples with balancing the need for efficiency with high quality patient care, Impinj (NASDAQ: PI), a leading provider and pioneer of RAIN RFID solutions for identifying, locating and authenticating everyday items, has organized a discussion with four of the institutions paving the way with implementation of cutting edge technologies. Coinciding with the 2017 HIMSS Annual Conference, Impinj will host a breakfast panel on Tuesday, Feb. 21 featuring executives from Memorial Sloan Kettering Cancer Center, the Medical University of South Carolina, Inova Fairfax Medical Campus, and the Veterans Administration Salt Lake City.




GrowGeneration Acquires All the Assets of Sonoma Hydro Creating a $2.5 Million Northern California Retail Distribution Center

Wed, 15 Feb 2017 10:00:00 EST

DENVER, CO--(Marketwired - February 15, 2017) - GrowGeneration Corp. (OTCQB: GRWG), GrowGeneration ("GrowGen" or the "Company"), one of the largest specialty retail hydroponic and organic gardening store chains, selling to both the commercial and home cannabis markets, with currently 10 locations in Colorado, 1 location in California and 1 location in Las Vegas, NV, today announced that it has acquired all of the assets of Sonoma Hydro and signed a 5-year lease on a 8,000 square foot facility in Santa Rosa, CA. The Sonoma Hydro location, one of the original hydroponic stores in what is known as the Emerald Triangle, will serve as a retail and warehouse location servicing the growing number of both commercial and home growers in the Northern California market.




Progressive Care Releases Open Letter to Shareholders

Wed, 15 Feb 2017 09:08:17 EST

Open Letter to Shareholders Summarizes Recent Milestones




AXIM Biotech Offers the Broadest Pipeline in the Cannabis Industry -- SECFilings.com

Wed, 15 Feb 2017 09:00:00 EST

REDONDO BEACH, CA--(Marketwired - Feb 15, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing AXIM® Biotechnologies Inc.'s (OTCQB: AXIM) recently expanded drug development pipeline.




InfinityQS Advocates Enterprise Visibility as First Step to Industry 4.0

Wed, 15 Feb 2017 08:37:00 EST

Digital transformation requires centralized, real-time, automated data collection to unlock the potential to increase output, decrease costs, and improve quality across manufacturing operations




Marijuana Company of America Transitions into Cultivation and Processing With New Agreement

Wed, 15 Feb 2017 08:30:00 EST

BONSALL, CA--(Marketwired - Feb 15, 2017) - MARIJUANA COMPANY OF AMERICA ("MCOA" or the "Company") (OTC: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce that it has entered into a non-binding Letter of Intent ("LOI") while performing due diligence to finalize a joint venture agreement with Bougainville Ventures, Inc. ("BV") for the purpose of housing tenant growers engaging in the cultivation, processing and commercial availability of legal marijuana in the State of Washington.




Nutra Pharma and Nyloxin Featured on NBC News-Miami

Wed, 15 Feb 2017 08:30:00 EST

Nutra Pharma's over the counter (OTC) products, Nyloxin(R) and Pet Pain-Away(TM), were featured on the NBC News Miami affiliate last night




Aevi Genomic Medicine Announces 2017 Investor Day

Wed, 15 Feb 2017 08:00:00 EST

PHILADELPHIA, PA--(Marketwired - Feb 15, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced that it will host an Investor Day with senior management and key opinion leaders to discuss AEVI-001 and opportunities in the ADHD market. The event will be held at the NASDAQ Market Site in New York City on Wednesday, February 22, 2017 with breakfast beginning at 8:30 a.m. Eastern Time and speaker presentations beginning at 9:00 a.m. Eastern Time.




ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries

Wed, 15 Feb 2017 08:00:00 EST

LOS ANGELES, CA--(Marketwired - February 15, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today the "New Intellectual Property" & "New Products Initiative" will focus on creating new products and filing new patents to treat pain and certain diseases associated with inflammation. The company expects treatment success of ViaDerma's "Proprietary Delivery System" for several diseases by finding the "Optimal Transdermal Delivery" of CBD's & THC to the localized treatment area and into the blood stream. With regards to the patent pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The provisional patent application using the combination of CBD's with the delivery system was originally filed in 2014, and a new provisional patent will be filed this week. The patent pending transdermal system can deliver medications and nutrients into the body through the skin.




From Market Compliance to Business Supply: The Necessity for Serialization, New Webinar Hosted by Xtalks

Wed, 15 Feb 2017 07:30:00 EST

TORONTO, ON--(Marketwired - February 15, 2017) - Mario R. Scigliano, Serialization and Automation Manager at CordenPharma Latina S.p.A will address the necessity of serialization from market compliance to business supply, covering all aspects from line choice and regulation approach to management of data and related products. The live event will take place on Wednesday, March 8th, 2017 at 4pm CET (10am EST).




Amedica Granted 180-Day Extension by NASDAQ to Regain Compliance with Minimum Bid Price Rule

Wed, 15 Feb 2017 07:20:00 EST

SALT LAKE CITY, UT--(Marketwired - Feb 15, 2017) - Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, announced today that on February 14, 2017, it received notification from the NASDAQ Stock Market indicating that the Company will have an additional 180-day grace period, until August 14, 2017, to regain compliance with NASDAQ's $1.00 minimum bid requirement. The notification indicated that the Company did not regain compliance during the initial 180-day grace period provided under the rule. In accordance with NASDAQ Marketplace Rule 5810(c)(3)(A), the Company is eligible for the additional grace period because it meets the initial listing requirements for the NASDAQ Capital Market except for the bid price and provided written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.




Renowned Homeland Security Experts Take The Stage At Milipol Asia-Pacific 2017 Conference

Tue, 14 Feb 2017 22:30:00 EST

SINGAPORE--(Marketwired - Feb 14, 2017) - The highly acclaimed Milipol Asia-Pacific Conference, returns this year from 4 to 6 April 2017 at the Sands Expo and Convention Centre, with a world class line-up of international speakers who will be sharing their latest insights on the homeland security environment. Themed "Emerging Threats -- The Case for Collaborative Public Safety", the three-day conference will expound on how governments and private organisations can build an effective internal and cross-border collaborative approach in tackling emerging threats to homeland security. 




The Alliance for Regenerative Medicine Releases Statement in Response to National Academies Report on Human Genome Editing

Tue, 14 Feb 2017 15:22:32 EST

WASHINGTON, DC--(Marketwired - Feb 14, 2017) - The National Academies of Sciences, Engineering and Medicine today issued a report that examines the scientific, clinical, ethical, legal and social implications of human genome editing. The Alliance for Regenerative Medicine (ARM) believes that genomic medicines, including genome editing, hold great promise for the treatment of a multitude of hereditary and acquired diseases where there is presently no effective treatment available.




Noraxon Introduces the World's First USB-Powered Compact HD Camera System with Integrated LED for Biomechanics Research

Tue, 14 Feb 2017 12:00:00 EST

NiNOX(TM) Cameras Feature Fast Frame Rates to Deliver Visual Reference and Real-time Synchronization




Cosmos Holdings, Inc. Acquires Decahedron Ltd.

Tue, 14 Feb 2017 11:06:01 EST

CHICAGO, IL--(Marketwired - Feb 14, 2017) - Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced today that the Company acquired 100% of the shares of Decahedron Ltd, a privately held company located in Harlow, United Kingdom just north of London. 




Invivoscribe anuncia Acuerdo de Colaboración a largo plazo con Illumina y planea lanzamiento de kits de ensayo IVD basados en NGS

Tue, 14 Feb 2017 11:01:56 EST

SAN JOSÉ, CA--(Marketwired - Feb 14, 2017) - Invivoscribe(R) Technologies Inc., una compañía internacional con décadas de experiencia ofreciendo soluciones de pruebas de clonalidad y biomarcador para los campos de oncología y diagnóstico molecular personalizado (R) y medicina molecular personalizada (R), anuncia hoy su acuerdo de colaboración a largo plazo con Illumina(R) Inc., para el desarrollo y comercialización de ensayos de diagnóstico in vitro (IVD) para la plataforma de secuenciación de próxima generación (NGS) MiSeqDx(R). Este acuerdo permite a Invivoscribe traer ensayos de IVD a través de la FDA, conjuntamente con el software de bioinformática asociado, para venta y distribución en Estados Unidos.




LogicStream Health Deploys v6.0 of Clinical Process Measurement Platform

Tue, 14 Feb 2017 10:37:58 EST

MINNEAPOLIS, MN--(Marketwired - Feb 14, 2017) - LogicStream Health, Inc. announced today that version 6.0 of its Clinical Process Measurement platform has been deployed into production at all its client sites. The latest release from the company, which delivers better processes and better outcomes, solidifies the Clinical Process Measurement framework previously available. All the functionality of the solution will be on display at Booth 875 during the HIMSS 17 conference in Orlando, Fla., February 19 to 23, 2017.




ProcessUnity Updates Risk and Compliance Management Platform with Winter 2017 Release

Tue, 14 Feb 2017 10:01:00 EST

Newest Version of Cloud-based Suite Expands Reporting and Dashboard Capabilities; Increases Configuration Options




Aldeyra Therapeutics, Inc. Prices Public Offering of Common Stock

Tue, 14 Feb 2017 09:39:45 EST

LEXINGTON, MA--(Marketwired - Feb 14, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the pricing of an underwritten public offering of 2,222,222 shares of its common stock at a price to the public of $4.50 per share. In connection with the offering, Aldeyra granted the underwriters a 30-day option to purchase 333,333 additional shares of common stock. All of the shares in the offering are being sold by Aldeyra. This offering is expected to close on or about February 17, 2017 subject to customary closing conditions.




Marina Biotech Announces Key Additions to its Executive Management Team

Tue, 14 Feb 2017 09:20:00 EST

CITY OF INDUSTRY, CA--(Marketwired - Feb 14, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced the appointment of Larn Hwang, Ph.D. as Chief Scientific Officer and Mihir Munsif as Chief Operating Officer.




SinglePoint Diversifies Operations & Cleans Up Financials -- CFN Media

Tue, 14 Feb 2017 09:15:00 EST

SEATTLE, WA--(Marketwired - Feb 14, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing recent developments and progress made by SinglePoint, Inc. (OTC PINK: SING).




SYSPRO Canada Extends Competitive Advantage with Expansion of Value Added Reseller Partner Network

Tue, 14 Feb 2017 09:00:00 EST

Strategic alliance with PAL Solutions for Business strengthens support for ERP solutions in Atlantic Canada




Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits

Tue, 14 Feb 2017 09:00:00 EST

SAN DIEGO, CA--(Marketwired - Feb 14, 2017) - Invivoscribe® Technologies Inc., an international company with decades of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® and personalized molecular medicine®, announces today its long-term collaboration agreement with Illumina® Inc., to develop and commercialize in vitro diagnostic (IVD) assays for the next-generation sequencing (NGS) MiSeqDx® platform. This agreement allows Invivoscribe to bring IVD assays through the FDA, together with the associated bioinformatics software, for sale and distribution in the US.




StoneCalibre Portfolio Company Anatrace Acquires Modern Reagents and Screens Provider Molecular Dimensions

Tue, 14 Feb 2017 09:00:00 EST

LOS ANGELES, CA--(Marketwired - February 14, 2017) - StoneCalibre is pleased to announce that its portfolio company, Anatrace, has completed the acquisition of Molecular Dimensions Ltd. ("Molecular Dimensions" or the "Company"), a Cambridge, UK based leading supplier of modern screens, reagents, other consumables and instrumentation for structural biology research.




Invivoscribe anuncia assinatura de Contrato de Colaboração de Longo Prazo com a Illumina e planeja o lançamento dos Kits de ensaio de IVD de NGS

Tue, 14 Feb 2017 09:00:00 EST

SAN DIEGO, CA--(Marketwired - Feb 14, 2017) - A Invivoscribe(R) Technologies Inc., uma empresa global com mais de 20 anos de experiência com fornecimento de soluções para testes de clonalidade e biomarcador para os campos de oncologia e diagnósticos moleculares personalizados (personalized molecular diagnostics(R)) e de medicina molecular personalizada (personalized molecular medicine(R)), anunciou hoje que fechou um contrato de colaboração de longo prazo com a Illumina(R) Inc., para o desenvolvimento e comercialização de ensaios de diagnóstico in vitro (in vitro diagnostic - IVD) para a plataforma MiSeqDx(R) de sequenciamento da próxima geração (next-generation sequencing - NGS). Este contrato permite que a Invivoscribe leve o ensaio de IVD por meio do FDA, juntamente com o software de bioinformática para venda e distribuição nos EUA.




StoneCalibre-Portfolio-Unternehmen Anatrace erwirbt Molecular Dimensions, einen Anbieter von modernen Reagenzien und Testverfahren

Tue, 14 Feb 2017 09:00:00 EST

LOS ANGELES, KALIFORNIEN--(Marketwired - 14. Februar 2017) - StoneCalibre freut sich bekanntzugeben, dass sein Portfolio-Unternehmen Anatrace die Übernahme des Unternehmens Molecular Dimensions Ltd. ("Molecular Dimensions" oder das "Unternehmen") abgeschlossen hat. Dieses Unternehmen hat seinen Sitz in Cambridge im Vereinigten Königreich und ist ein führender Anbieter von modernen Testverfahren, Reagenzien, Verbrauchsmaterialien und Instrumenten für die strukturbiologische Forschung.




Propanc Successfully Completes Low Dose Group for GLP-Compliant 28-Day Repeat-Dose Toxicity Study

Tue, 14 Feb 2017 08:30:00 EST

In-Life Phase for Middle and High Dose Groups Set to Commence Immediately




NuGene International Appoints John Ohanesian as Chief Strategic Advisor, Hair

Tue, 14 Feb 2017 08:00:00 EST

Ohanesian Led Bosley, Inc.'s Growth to Worldwide Hair Restoration Leadership




Vinergy Resources/MJ BioPharma Announces Breakthrough in Oral Cannabinoid Strip and Time Release Capsule Technologies

Tue, 14 Feb 2017 08:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 14, 2017) - Vinergy Resources Ltd. ("Vinergy" or the "Company")(CSE:VIN)(CSE:VIN.CN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce a major breakthrough while conducting research and development on oral cannabinoid complex (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabinol (CBN) and Terpenes) delivery strips and controlled time release capsule technology. This novel approach will be the basis for several products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of the cannabinoid complex into the body.




Nephros Announces Appointment of Andrew Astor as Chief Financial Officer

Tue, 14 Feb 2017 07:30:00 EST

Technology Industry Veteran Andrew Astor Hired to Support Growth and Business Momentum




Desiccant Dehumidification for Energy Efficient Drying of Gelatine and HPMC Capsules, New Webinar Hosted by Xtalks

Tue, 14 Feb 2017 07:30:00 EST

TORONTO, ON--(Marketwired - February 14, 2017) - During manufacturing of gelatine and HPMC capsules, efficient and carefully controlled drying is essential for ensuring product quality and consistence. Users of Munters' desiccant dehumidification have reported faster and more consistent drying times for freshly produced capsules thus allowing higher production volume and lower rates of non-compliant product, which in turn reduces production costs and fault finding efforts. These dehumidification solutions have the additional benefits of being energy efficient, hygienic and easy to maintain.




Adgero Biopharmaceuticals Holdings, Inc. Expands Executive Management Team with Appointment of Jane M. Maida as Chief Financial Officer

Tue, 14 Feb 2017 07:00:00 EST

PRINCETON, NJ--(Marketwired - February 14, 2017) - Adgero Biopharmaceuticals Holdings, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious oncology indications, announced today that it has appointed Jane M. Maida as Chief Financial Officer and Vice President of Finance.




Aldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock

Mon, 13 Feb 2017 16:01:00 EST

LEXINGTON, MA--(Marketwired - Feb 13, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aldeyra also expects to grant the underwriters a 30-day option to purchase additional shares of common stock. All of the shares in the offering are to be sold by Aldeyra, with net proceeds to be used for the continued development of Aldeyra's lead compound, ADX-102, and other product candidates, including further clinical testing of ADX-102, as well as for research and development activities, working capital and other general corporate purposes.




Advantech to Showcase New Products at HIMSS 2017

Mon, 13 Feb 2017 13:43:41 EST

Leading Technology Product, Solutions and Services Provider to Exhibit Diverse Set of Healthcare IT Hardware and Software Offerings at Important Industry Conference




Clinical Utility Study Demonstrating Improved Patient Outcomes With Proove Pain Perception Published in the Peer-Reviewed Journal of Psychiatric Research

Mon, 13 Feb 2017 13:26:50 EST

Researchers from University of Southern California, Interventional Pain Institute, and Proove Biosciences Publish Clinical Utility Study Supporting Precision Medicine in Pain Perception




UC Irvine Offers New Online Master of Science in Pharmacology Degree Program

Mon, 13 Feb 2017 12:00:00 EST

Master's Degree is Part of the Department of Pharmacology in the School Of Medicine at UC Irvine




DirectTrust Issues Recommendations to Significantly Improve Usability of EHRs and Health IT Applications Providing Secure Direct Messaging

Mon, 13 Feb 2017 09:15:00 EST

WASHINGTON, DC--(Marketwired - Feb 13, 2017) - DirectTrust today released for public comment a white paper containing more than 50 recommendations aimed at the more than 350 EHR vendors and HIT products' vendors that provide Direct Interoperability, urging them to significantly improve the usability of their products for secure, interoperable clinical messaging. The paper, "Feature and Function Recommendations to the HIT Industry to Optimize Clinician Usability of Direct Interoperability to Enhance Patient Care," was authored by a DirectTrust workgroup whose members are physicians and nurses with significant experience using Direct messaging to support health record sharing for care coordination and transitions of care. 




Review published in Nature Reviews Urology advises antibiotic resistance testing for M. genitalium sexually transmitted infection and potential "superbug"; SpeeDx ResistancePlus(TM) MG Test only CE-marked commercial test available for this purpose

Mon, 13 Feb 2017 09:00:00 EST

SYDNEY, AUSTRALIA--(Marketwired - Feb 13, 2017) - SpeeDx Pty. Ltd. today announced that the authors of the review, Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium, published in Nature Reviews Urology http://www.nature.com/nrurol/journal/vaop/ncurrent/full/nrurol.2016.268.html, recommended that appropriate M. genitalium diagnostic testing become available on a routine basis in clinical practice and should ideally be supplemented with molecular detection for antibiotic resistance. Currently, SpeeDx has the only commercially available test capable of simultaneously detecting the sexually transmitted infection (STI) M. genitalium and antibiotic resistance status. SpeeDx ResistancePlusT MG test is CE marked for sale in Europe and TGA approved for sale in Australia. SpeeDx plans to seek a de novo clearance for the test with the U.S. Food and Drug Administration this year.




Orgenesis Approved for Euro 12.3 Million European Grant for Further Development of Its Type 1 Diabetes Program

Mon, 13 Feb 2017 08:30:00 EST

GERMANTOWN, MD--(Marketwired - Feb 13, 2017) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its Belgian subsidiary, Orgenesis SPRL, has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) for a budget of EUR 12.3 million ($12.8 million) support program for the GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium. The project support will be for a period of three years commencing on January 1, 2017.




UA Multimedia Initiates Process to Change the Company Name and Ticker Symbol

Mon, 13 Feb 2017 08:30:00 EST

IRVINE, CA--(Marketwired - Feb 13, 2017) -  UA Multimedia, Inc. (OTC: UAMM), a technology and indoor growing solution provider, is pleased to announce that the Company has initiated the process to change its company name and ticker symbol.




Treos Bio Raises $8 Million in Private Investment Round

Mon, 13 Feb 2017 08:15:00 EST

Funding will carry company through early-stage clinical trial of its precision vaccine for colorectal cancer




Mount Tam Biotechnologies Announces TAM-03, a Novel Compound with Potential to Treat a Range of Cancer Types

Mon, 13 Feb 2017 08:00:00 EST

NOVATO, CA--(Marketwired - Feb 13, 2017) - Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, announces that it will advance a novel 'rapalog', TAM-03, for further development efforts with the ultimate goal of moving TAM-03 into the clinic to treat certain advanced cancers for which current therapies are inadequate. TAM-03 delivers a differentiated mTORC1:2 profile, one that is desirable for treating certain cancers.




Savaria Completes its Acquisition of Premier Lifts

Mon, 13 Feb 2017 08:00:00 EST

LAVAL, QUEBEC--(Marketwired - Feb. 13, 2017) - Savaria Corporation (TSX:SIS) ("Savaria"), one of North America's leaders in the accessibility industry, is pleased to report the successful completion of its previously announced acquisition of all the assets of Premier Lifts, Inc. ("Premier Lifts"), a leading elevator dealer in the Baltimore - Washington area, for a purchase price of approximately US $3.5 million (CDN $4.6 million).




Savaria complète l'acquisition de Premier Lifts

Mon, 13 Feb 2017 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - 13 fév. 2017) - Un des chefs de file nord-américains de l'industrie de l'accessibilité, Savaria Corporation (TSX:SIS) (« Savaria »), est heureuse d'annoncer qu'elle a complété l'acquisition annoncée précédemment de tous les actifs de Premier Lifts, Inc. («Premier Lifts»), un important distributeur d'ascenseurs de la région de Baltimore-Washington, pour un prix d'achat d'environ 3,5 millions $ US (4,6 millions $ CDN).




Helix BioPharma Corp. Conference Attendance 2017

Mon, 13 Feb 2017 07:45:00 EST

TORONTO, ON--(Marketwired - Feb 13, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, will be attending and/or presenting at the following conferences in the first half of 2017:




Designing an Effective Clinical Trial, New Webinar Hosted by Xtalks

Mon, 13 Feb 2017 07:30:00 EST

The session will focus on various aspects of designing and conducting clinical trials for submission to the FDA, as well as, communicating with FDA during the pre-submission and submission process